ANL Stock Forecast & Price Target

Adlai Nortye is supported by a differentiated RAS franchise that now has two clinical-stage assets in the clinic, with FDA “Study-May-Proceed” clearance for AN4035 in the U.S. and first patient dosed in Australia, reducing execution risk and validating the platform. AN9025 adds a second shot on goal in the same biologic pathway, and the company’s preclinical profile suggests stronger potency, durable pathway suppression, and possible intermittent dosing that could improve tolerability and combination potential in a broad RAS-mutant market. The setup is further strengthened by asymmetric valuation, with a market cap of about $0.7B versus peers at $3.8B and $35B, while key catalysts include AN9025 QD/QW dose-escalation data expected in 1H27 and AN4035 Phase 1a data in 2H27.

Adlai Nortye is facing a weak fundamental outlook because its lead RAS assets, especially AN9025, remain preclinical and unvalidated in humans, while the cited higher potency and long half-life could translate into toxicity, dose interruptions, and a narrower therapeutic window than hoped. The company has not yet generated any revenue from product sales, is not profitable, and is expected to see rising operating expenses as trials advance, creating liquidity risk if financing is unavailable or pipeline setbacks delay commercialization. Its investment case is further pressured by IP and freedom-to-operate uncertainty in the IP-sensitive panRAS(ON) space and by intense competition from better-resourced peers that could render its programs less compelling or non-competitive.